

Extracorporeal Tubing in the Roller Pump Raceway: Physical Changes and Particulate Generation

Allison J. Bednarski Spiwak, MS; Alexander Horbal, BS; Robert Leatherbury, BS; Derek J. Hansford, PhD

Circulation Technology Division and Department of Biomedical Engineering, Microfabrication, The Ohio State University, Columbus, Ohio

Presented at the 46th International Conference of the American Society of Extra-Corporeal Technology, Hilton Hotel, Lake Buena Vista, Florida, April 9–12, 2008.

Abstract: Plasticized polyvinyl chloride tubing is used as the blood conduit in the heart lung bypass circuit. The section in the roller pump undergoes rigorous compression. Fatigue leads to material changes in weight and length of the bulk material. Particles are released during normal pump operation. This study evaluates the time course of particle loss. Three segments of 1/2" ID tubing run in the raceway for 30-minute, 1-hour, or 2-hour. The fluid path of each segment includes an oxygenator; a castor oil blend was used for the prime. The 5 mL sample was acquired at 10 minute intervals. Raceway tubing segments were measured for a change in weight and length. The same procedure repeated with 1/4" ID and 3/8" ID tubing. All tubing increased at least 5 mm by the 2-hour trial. There were no remarkable changes in weight.

Particles were measured for size and percent volume. Tubing with 1/2" ID performed most consistently for particle release during all trials. Particles were observed as small as 1 nm. Particles as large as 3 micron could be confirmed. For all tubing there was particle release by 30 minutes. Perfusionists must consider tubing inner diameter and wall thickness in choosing the pPVC for the raceway in order to minimize particulate emboli. This research suggests that 3/8" ID tubing produces spalls inconsistently compared to 1/2" ID tubing. Thinner wall thickness tubing also has the potential to limit spall formation. **Keywords:** di-2-ethylhexyl phthalate, polyvinyl chloride, tubing, spallation, fatigue. *JECT. 2008;40:188–192*

Plasticized polyvinyl chloride (pPVC) tubing is used as the blood conduit in the heart lung machine. During cardiopulmonary bypass (CPB), this tubing is put under aggressive treatment by the roller heads. The roller head compresses the pPVC against the backing plate of the pump housing to propel the blood out of the tubing segment. This rigorous challenge leads to changes in the material properties of the pPVC. Changes to the material include loss of plasticizer and gain of blood path constituents such as water and pharmaceuticals (1–6). Plasticizer loss was caused by compression, leaching, and evaporation (1).

Spallation occurs when particles generate and release from the tubing. This process is known to occur in the raceway of the roller pump during normal pump operation (7–15). Images of the surface taken by scanning electron microscopy (SEM) show this process of particle formation (7–17). Tubing out of the packaging does not show the same process (10). SEM images show particle dimensions from 10 to 150 μm . Images by atomic force microscopy (AFM) show particles with 10-nm dimensions representative of changes in surface coating familiar to some prod-

ucts (12). The study by Uretzsky et al. (7) shows that spallation occurs rapidly in both uncoated pPVC and silicone tubing.

Medically, the concern is that release of foreign materials unfamiliar to the body might activate acute and chronic pathologies. Rossi and Schettler (18), in a white paper, "PVC & Healthcare," highlighted the exposure to plasticizer phthalates, specifically di-2-ethylhexyl phthalate (DEHP). Phthalates pose risk to reproduction, hepatomegaly, and can result in acute immune system response (3,18–22). As a consequence, the European Union (EU) restricts exposure to 48 $\mu\text{g}/\text{kg}/\text{d}$, which can be exceeded during a plasmapheresis session (19–22). There is common use of alternative pPVC or silicone pump boots in the EU. Alternative pPVC is available that does not use DEHP, and preliminary evaluation by SEM showed few if any fatigue patterns in 6 hours of exposure to roller pump treatment compared with traditional pPVC (Figure 1) (12,22).

The purpose of this experiment is to examine the aggressive treatment of tubing in the raceway. The goal is to examine physical properties and particle release during




Figure 1. Plasticized PVC. A, Tygon S-95-E tubing. Tubing inner surface after 6 hours of treatment by roller head pump > 100 rpm. Image width is ~30 μm across. Notice there were no distinctive patterns on the image. B, Traditional pPVC with DEHP after exposure to roller head compression. The surface suffers from cracks, craters, and material irregularities.

rigorous pump runs. The changes in physical and material properties may include changes in weight, length, and plasticity (3,11,14,23). Therefore, we will evaluate blood path tubing for CPB with different inner diameters (IDs) and different wall thicknesses. A trend in particle release may be an indicator of material stability for the purpose of CPB. Particle release may be limited to a specific time course based on tubing ID or wall thickness.

MATERIALS AND METHODS

Roller pumps (COBE Century, Arvada, CO) were prepared for different ID tubing. The necessary tubing guards and occlusions were set to accept $\frac{1}{4}$ ", $\frac{3}{8}$ ", or $\frac{1}{2}$ " pPVC tubing. Uncoated pPVC was chosen for the experiment. The tubing was taken from a collection of donated CPB custom tubing packs. Tubing sizes of $\frac{1}{2}$ ", $\frac{3}{8}$ ", and $\frac{1}{4}$ " ID

had outer wall thicknesses of $\frac{3}{32}$ ", $\frac{3}{32}$ ", and $\frac{1}{16}$ ", respectively. Three segments of the $\frac{1}{2}$ " ID tubing were cut to the length of the raceway. Before insertion, the tubing was measured for length and weight. The segments were loaded into the raceway against the backing plate. "Just under occluded" setting was followed per manufacturer instructions. The extracorporeal circuit path included polycarbonate connectors with luer lock to connect the test segment to $\frac{3}{8}$ " ID pPVC and a hollow fiber oxygenator with integral heater exchanger. The high flow stopcock on the luer lock distal to the raceway was used for sampling. Perfusate temperature was maintained at 32°C.

Perfusion solution was made of a mixture of 200 mL castor oil and 800 mL saline to encourage surface changes similar to other body fluid solutions (24). Castor oil is naturally occurring and inexpensive. Its amphiphilic nature is surface active. A viscous, non-volatile and non-drying oil, castor oil was chosen because it is known to influence the release of DEHP (14,21,22,25).

The pump was operated at 200 rpm for 30-minute, 1-hour, and 2-hour trials. Five milliliters of fluid was collected every 10 minutes. Note that the $\frac{1}{2}$ " ID trial began the first sample at 15 minutes. No waste was taken when the samples were drawn. The sample was drawn from high flow stopcocks (26). The fluid was stored in glass vials with screw top lids at room temperature. The samples were kept from light during storage. At the end point, the tubing was weighed and measured. The same process was completed for the $\frac{3}{8}$ " ID and the $\frac{1}{4}$ " ID tubing.

Particle size analysis was accomplished by dynamic light scattering laser technology on the Malvern Zetasizer (Malvern Instruments, Worcestershire, UK). A suitable cuvette held at least 0.75 mL of the test fluid. The carefully handled cuvette was introduced to the sampling port. Particles from <1 nm to 3 μm were analyzed. The volume of the sample occupied by the particles was reported as a percentage.

Analysis of variance was used to determine difference of treatments for time, ID, or wall thickness. Excel was used to generate statistics, graphs, and tables (Microsoft, Redwood, WA).

RESULTS

At 2 hours, all tubing had lengthened by at least 5 mm. The $\frac{3}{8}$ " ID tubing lengthened from 18.5" to 18.8". This was a percent change of 1.7%. At 60 minutes, the $\frac{3}{8}$ " ID tubing had increased by .7%. There was a 1.5% change in length for the $\frac{1}{2}$ " ID tubing after 2 hours. No changes were seen with the 60- or 30-minute $\frac{1}{2}$ " tubing lengths. The same was true for the $\frac{1}{4}$ " ID tubing. The difference in pre- and post-weight of all tubing segments was negligible.

Figure 3 was the result of a particle measurements for




Figure 2. Change in length. The pPVC gained in length over time at all ID. The change in length with respect to time was significant, $p = .001$. The greatest change in length occurred at 2 hours.




Figure 3. Volume distribution graph. Description of particle volume in prime of $3/8$ " ID tubing after exposure to roller head compression. Particles in this example were measured at 100 nm and >1 μm .

each tubing segment for each time point collected. The $1/4$ " ID samples were limited to 30- and 60-minute trials. Each ID is graphed separately.

Particles measured from 1 nm to >3 μm in volume in all tubing sizes (Figure 4). Figure 3 shows a characteristic plot. Samples were limited to two peaks at most in the volume analysis. There was no consistency of multiple peaks. Particle measurements were not consistent from one 10-minute sample to the next in terms of size or volume.

The particle release occurred in spurts. Small $1/4$ " ID tubing took longer to release particles. The late release of particles occurred at 30, 40, and 60 minutes. The most consistent release of particles was in the largest diameter tubing. The particle intensity remained measurable throughout all 2 hours. The samples at 35 and 75 minutes did not show peaks.

The $3/8$ " tubing released particles early in the 30- and 60-minute trials. This was inconsistent in the 2-hour trial, when particle release did not occur until 40 minutes. Fifteen trials showed .1 μm or larger particles for $1/2$ " ID tubing; nine showed 1 μm or larger particles. Seven trials showed .1 μm release for $3/8$ " ID tubing; four showed 1 μm or larger particles.




Figure 4. Particle release. All tubing showed particle release. The $1/2$ " tubing registered particles regularly and most consistently. Both the $3/8$ " and $1/2$ " segments showed late and early particle release, whereas the $1/4$ " showed particle release late in the trials. It is believed particle release occurred and equilibrated with the pattern repeating.

DISCUSSION

The material properties of the tubing changed during the compression trials. Tubing length increased in a time-dependent response. With continued use for 24 hours, the tubing in this study would have lengthened 2.4 cm, or almost 1 in. Work by Snyder et al. (14) showed changes in length approaching 650% after 21 days with $3/8$ " ID tubing. The change in length may indicate changes in the polymer fiber configuration. Length change may represent a loss of elasticity.

The sample preparation showed little change in weight over the course of the treatment. In this study, we expected minimal weight change. Shashoa (1) showed that, at room temperature, DEHP was lost from tubing stored in low-density polyethylene bags at the greatest rate compared with high relative humidity environments. High humidity showed no weight change. Tubing hazed from the humidity because the water was retained (1). In samples left exposed to room air, the greatest loss was discovered in the first several days, with little further ambient loss (1). This is comparable to other DEHP migration studies. In polyethylene glycol-coated pPVC tubes 10% weight loss occurred at 10 hours, leading to a plateau of 30% weight loss at 40 hours (19).

Our previous work has imaged particles on the tubing used in the pump raceway (12). Peek et al. (8) reported

ACKNOWLEDGMENTS

We thank Drs. Kuppusamy and Pandian, Center for Biomedical EPR Spectroscopy and Imaging, Davis Heart and Lung Research Institute, for use of the Zetasizer particle counter. We recognize colleagues and alumni for support of student education and research projects in Circulation Technology including materials from COBE Cardiovascular, Terumo Medical, Medtronic, and Saint-Gobain. We appreciate the help of Kate Matusak and Todd Melone in preparing this manuscript.

REFERENCES

1. Shashoua YR. Effect of indoor climate on the rate and degradation mechanism of plasticized poly (vinyl chloride). *Polym Degrad Stabil.* 2003;81:29–36.
2. Burkhart HM, Joyner N, Niles S, et al. Presence of plasticizer di-(2-ethylhexyl)phthalate in primed extracorporeal circulation circuits. *ASAIO J.* 2007;53:365–7.
3. Gourlay T. Biomaterial development for cardiopulmonary bypass. *Perfusion.* 2001;16:381–90.
4. Preston TJ, Hodge AB, Riley JB, Leib-Sargal C, Nicol KK. In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit. *J Extra Corpor Technol.* 2007;39:234–7.
5. Bhatt-Mehta V, Annich G. Sedative clearance during extracorporeal membrane oxygenation. *Perfusion.* 2005;20:309–15.
6. Urban K, Redford D, Larson DF. Insulin binding to the cardiopulmonary bypass biomaterials. *Perfusion.* 2007;22:207–10.
7. Uretzky G, Landsburg G, Cohn D, Wax Y, Borman JB. Analysis of microembolic particles originating in extracorporeal circuits. *Perfusion.* 1987;2:9–17.
8. Peek GJ, Thompson A, Killer HM, Firmin RK. Spallation performance of extracorporeal membrane oxygenation tubing. *Perfusion.* 2000;15:457–66.
9. Kurusz M, Christman EW, Williams EH, Tyers GF. Roller pump induced tubing wear: Another argument in favor of arterial line filtration. *J Extra Corpor Technol.* 1980;12:49–59.
10. Kurusz M, Williams DR. Blood surfaces in the extra corporeal circuit: a scanning electron microscopic study, 1975. *J Extra Corpor Technol.* 2004;36:78–90.
11. Kim SC, Yoon HJ, Lee JW, Yu J, Park E, Chi S. Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles. *Int J Pharm.* 2005;293:303–10.
12. Stonerock B, Grady K, Riley J, Spiwak A. Roller pump fatigue in coated vs. non-coated tubing. *J Extra Corpor Technol.* 2006;38:99.
13. Marshall L. Filtration in cardiopulmonary bypass: past, present and future. *Perfusion.* 1988;3:135–47.
14. Snyder EJ, McElwee DL, Harb HM, et al. Investigation of fatigue failure of S-65-HL “super tygon” roller pump tubing. *J Extra Corpor Technol.* 1996;28:79–87.
15. Kemna GD, Docherty JP. Why filter the cardiopulmonary circuit pre-bypass? *J Extra Corpor Technol.* 1979;11:119–30.
16. Subramanian P, Ainsworth P, Cassey J, Phelan D. Lost bits: Particle shedding with polyvinyl chloride intravenous administration sets. *Pediatr Surg Int.* 2002;18:658–61.
17. Brooks JD, Beauchamp RA, Magrath RA, Clark RE. Efficacy of particulate removal by a pre-bypass filter with different oxygenation systems. *J Extra Corpor Technol.* 1979;11:175–82.
18. Rossi M, Schettler T. PVC & Healthcare. Setting Healthcare’s Environmental Agenda. October 16, 2000. San Francisco, CA.
19. Lakshmi S, Jayakrishnan A. Migration resistant, blood-compatible plasticized polyvinyl chloride for medical and related applications. *Artif Organs.* 1998;22:222–9.
20. Koch HM, Bolt HM, Preuss R, Eckstein R, Weisbach V, Angerer J. Intravenous exposure to di(2-ethylhexyl)phthalate (DEHP): metabolites of DEHP in urine after a voluntary platelet donation. *Arch Toxicol.* 2005;79:689–93.
21. Hanawa T, Marumatsu E, Asakawa K, et al. Investigation of the release behavior of diethylhexyl phthalate from the polyvinyl-chloride tubing for intravenous administration. *Int J Pharm.* 2000;210:109–15.
22. Hanawa T, Naoko E, Masahiko S, et al. Release behavior of diethylhexyl phthalate from the polyvinyl-chloride tubing used for intravenous administration and the plasticized PVC membrane. *Int J Pharm.* 2005;297:30–7.
23. Rusu M, Ursu M, Rusu D. Poly(vinyl chloride) and poly(ϵ -caprolactone) blends for medical use. *J Thermoplastic Composite Mater.* 2006;19:173–89.
24. McGovern JG, Garvin CP, Jones DS, Woolfson AD, Gorman SP. Modification of biomaterial surface characteristics by body fluids in vitro. *Int J Pharm.* 1997;149:251–4.
25. Ogunniyi DS. Castor oil: A vital industrial raw material. *Bioresour Technol.* 2006;97:1086–91.
26. Jones FJ, Weinberger CB. Screening effects when sampling suspensions in laminar flow through pores. *AIChE J.* 1997;43:2405–14.
27. Jeong JH, Sugii Y, Minamiyama M, Okamoto K. Measurement of RBC deformation and velocity in capillaries in vivo. *Microvasc Res.* 2006;71:212–7.
28. Pastoriza-Pinol JV, McMillan J, Smith BF, et al. An analysis of micro embolic particles originating in the extra-corporeal circuit before bypass. *J Extra Corpor Technol.* 1979;11:221–8.